Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

Effect of geographic isolation on the nasal virome of indigenous children.

Altan E, Dib JC, Gulloso AR, Juandigua DE, Deng X, Bruhn R, Hildebrand K, Freiden P, Yamamoto J, Schultz-Cherry S, Delwart E.

J Virol. 2019 Jun 12. pii: JVI.00681-19. doi: 10.1128/JVI.00681-19. [Epub ahead of print]

PMID:
31189707
2.

Wild birds in Chile Harbor diverse avian influenza A viruses.

Jiménez-Bluhm P, Karlsson EA, Freiden P, Sharp B, Di Pillo F, Osorio JE, Hamilton-West C, Schultz-Cherry S.

Emerg Microbes Infect. 2018 Mar 29;7(1):44. doi: 10.1038/s41426-018-0046-9.

3.

Persistent Infections with Diverse Co-Circulating Astroviruses in Pediatric Oncology Patients, Memphis, Tennessee, USA.

Cortez V, Freiden P, Gu Z, Adderson E, Hayden R, Schultz-Cherry S.

Emerg Infect Dis. 2017 Feb;23(2):288-290. doi: 10.3201/eid2302.161436.

4.

Swine Influenza Virus (H1N2) Characterization and Transmission in Ferrets, Chile.

Bravo-Vasquez N, Karlsson EA, Jimenez-Bluhm P, Meliopoulos V, Kaplan B, Marvin S, Cortez V, Freiden P, Beck MA, Hamilton-West C, Schultz-Cherry S.

Emerg Infect Dis. 2017 Feb;23(2):241-251. doi: 10.3201/eid2302.161374.

5.

Oral Administration of Astrovirus Capsid Protein Is Sufficient To Induce Acute Diarrhea In Vivo.

Meliopoulos VA, Marvin SA, Freiden P, Moser LA, Nighot P, Ali R, Blikslager A, Reddivari M, Heath RJ, Koci MD, Schultz-Cherry S.

MBio. 2016 Nov 1;7(6). pii: e01494-16. doi: 10.1128/mBio.01494-16.

6.

Type I Interferon Response Limits Astrovirus Replication and Protects against Increased Barrier Permeability In Vitro and In Vivo.

Marvin SA, Huerta CT, Sharp B, Freiden P, Cline TD, Schultz-Cherry S.

J Virol. 2015 Dec 9;90(4):1988-96. doi: 10.1128/JVI.02367-15. Print 2016 Feb 15.

7.

Non-Human Primates Harbor Diverse Mammalian and Avian Astroviruses Including Those Associated with Human Infections.

Karlsson EA, Small CT, Freiden P, Feeroz MM, Matsen FA 4th, San S, Hasan MK, Wang D, Jones-Engel L, Schultz-Cherry S.

PLoS Pathog. 2015 Nov 16;11(11):e1005225. doi: 10.1371/journal.ppat.1005225. eCollection 2015.

8.

Human norovirus culture in B cells.

Jones MK, Grau KR, Costantini V, Kolawole AO, de Graaf M, Freiden P, Graves CL, Koopmans M, Wallet SM, Tibbetts SA, Schultz-Cherry S, Wobus CE, Vinjé J, Karst SM.

Nat Protoc. 2015 Dec;10(12):1939-47. doi: 10.1038/nprot.2015.121. Epub 2015 Oct 29.

9.

Safety and immunogenicity of an intranasal Sendai virus-based human parainfluenza virus type 1 vaccine in 3- to 6-year-old children.

Adderson E, Branum K, Sealy RE, Jones BG, Surman SL, Penkert R, Freiden P, Slobod KS, Gaur AH, Hayden RT, Allison K, Howlett N, Utech J, Allay J, Knight J, Sleep S, Meagher MM, Russell CJ, Portner A, Hurwitz JL.

Clin Vaccine Immunol. 2015 Mar;22(3):298-303. doi: 10.1128/CVI.00618-14. Epub 2014 Dec 31.

10.

Human H7N9 and H5N1 influenza viruses differ in induction of cytokines and tissue tropism.

Meliopoulos VA, Karlsson EA, Kercher L, Cline T, Freiden P, Duan S, Vogel P, Webby RJ, Guan Y, Peiris M, Thomas PG, Schultz-Cherry S.

J Virol. 2014 Nov;88(22):12982-91. doi: 10.1128/JVI.01571-14. Epub 2014 Sep 10.

11.

Seroepidemiology of astrovirus MLB1.

Holtz LR, Bauer IK, Jiang H, Belshe R, Freiden P, Schultz-Cherry SL, Wang D.

Clin Vaccine Immunol. 2014 Jun;21(6):908-11. doi: 10.1128/CVI.00100-14. Epub 2014 Apr 30.

12.

Crystal structure of the avian astrovirus capsid spike.

DuBois RM, Freiden P, Marvin S, Reddivari M, Heath RJ, White SW, Schultz-Cherry S.

J Virol. 2013 Jul;87(14):7853-63. doi: 10.1128/JVI.03139-12. Epub 2013 May 8.

13.

Prevalence and characterization of influenza viruses in diverse species in Los Llanos, Colombia.

Karlsson EA, Ciuoderis K, Freiden PJ, Seufzer B, Jones JC, Johnson J, Parra R, Gongora A, Cardenas D, Barajas D, Osorio JE, Schultz-Cherry S.

Emerg Microbes Infect. 2013 Apr;2(4):e20. doi: 10.1038/emi.2013.20. Epub 2013 Apr 24.

14.

UV-inactivated vaccinia virus (VV) in a multi-envelope DNA-VV-protein (DVP) HIV-1 vaccine protects macaques from lethal challenge with heterologous SHIV.

Jones BG, Sealy RE, Zhan X, Freiden PJ, Surman SL, Blanchard JL, Hurwitz JL.

Vaccine. 2012 May 2;30(21):3188-95. doi: 10.1016/j.vaccine.2012.03.001. Epub 2012 Mar 14.

15.

Increased pathogenicity of a reassortant 2009 pandemic H1N1 influenza virus containing an H5N1 hemagglutinin.

Cline TD, Karlsson EA, Freiden P, Seufzer BJ, Rehg JE, Webby RJ, Schultz-Cherry S.

J Virol. 2011 Dec;85(23):12262-70. doi: 10.1128/JVI.05582-11. Epub 2011 Sep 14.

16.

Seroprevalence of antibodies to influenza A/H1N1/2009 among transmission risk groups after the second wave in Mexico, by a virus-free ELISA method.

Elizondo-Montemayor L, Alvarez MM, Hernández-Torre M, Ugalde-Casas PA, Lam-Franco L, Bustamante-Careaga H, Castilleja-Leal F, Contreras-Castillo J, Moreno-Sánchez H, Tamargo-Barrera D, López-Pacheco F, Freiden PJ, Schultz-Cherry S.

Int J Infect Dis. 2011 Nov;15(11):e781-6. doi: 10.1016/j.ijid.2011.07.002. Epub 2011 Aug 19.

17.

Receptor-binding specificity of the human parainfluenza virus type 1 hemagglutinin-neuraminidase glycoprotein.

Alymova IV, Portner A, Mishin VP, McCullers JA, Freiden P, Taylor GL.

Glycobiology. 2012 Feb;22(2):174-80. doi: 10.1093/glycob/cwr112. Epub 2011 Aug 16.

18.

Specific recognition of influenza A/H1N1/2009 antibodies in human serum: a simple virus-free ELISA method.

Alvarez MM, López-Pacheco F, Aguilar-Yañez JM, Portillo-Lara R, Mendoza-Ochoa GI, García-Echauri S, Freiden P, Schultz-Cherry S, Zertuche-Guerra MI, Bulnes-Abundis D, Salgado-Gallegos J, Elizondo-Montemayor L, Hernández-Torre M.

PLoS One. 2010 Apr 14;5(4):e10176. doi: 10.1371/journal.pone.0010176.

19.

Heterologous Prime-Boost HIV-1 Vaccination Regimens in Pre-Clinical and Clinical Trials.

Brown SA, Surman SL, Sealy R, Jones BG, Slobod KS, Branum K, Lockey TD, Howlett N, Freiden P, Flynn P, Hurwitz JL.

Viruses. 2010 Feb 1;2(2):435-467.

20.

Preclinical and clinical development of a multi-envelope, DNA-virus-protein (D-V-P) HIV-1 vaccine.

Sealy R, Slobod KS, Flynn P, Branum K, Surman S, Jones B, Freiden P, Lockey T, Howlett N, Hurwitz JL.

Int Rev Immunol. 2009;28(1):49-68. doi: 10.1080/08830180802495605. Review.

21.

First phase I clinical trial of an HIV-1 subtype D gp140 envelope protein vaccine: immune activity induced in all study participants.

Hurwitz JL, Lockey TD, Jones B, Freiden P, Sealy R, Coleman J, Howlett N, Branum K, Slobod KS.

AIDS. 2008 Jan 2;22(1):149-51.

PMID:
18090404
22.

HIV-1 vaccine development: tackling virus diversity with a multi-envelope cocktail.

Hurwitz JL, Zhan X, Brown SA, Bonsignori M, Stambas J, Lockey TD, Sealy R, Surman S, Freiden P, Jones B, Martin L, Blanchard J, Slobod KS.

Front Biosci. 2008 Jan 1;13:609-20. Review.

PMID:
17981574
23.

A Multi-Vector, Multi-Envelope HIV-1 Vaccine.

Hurwitz JL, Zhan X, Brown SA, Bonsignori M, Stambas J, Lockey TD, Jones B, Surman S, Sealy R, Freiden P, Branum K, Slobod KS.

J Pediatr Pharmacol Ther. 2007 Apr;12(2):68-76. doi: 10.5863/1551-6776-12.2.68.

24.

Clade, Country and Region-specific HIV-1 Vaccines: Are they necessary?

Slobod KS, Coleclough C, Brown SA, Stambas J, Zhan X, Surman S, Jones BG, Zirkel A, Freiden PJ, Brown B, Sealy R, Bonsignori M, Hurwitz JL.

AIDS Res Ther. 2005 Apr 28;2(1):3.

25.

HIV vaccine rationale, design and testing.

Slobod KS, Coleclough C, Bonsignori M, Brown SA, Zhan X, Surman S, Zirkel A, Jones BG, Sealy RE, Stambas J, Brown B, Lockey TD, Freiden PJ, Doherty PC, Blanchard JL, Martin LN, Hurwitz JL.

Curr HIV Res. 2005 Apr;3(2):107-12. Review.

PMID:
15853717
26.

Long lived multi-isotype anti-HIV antibody responses following a prime-double boost immunization strategy.

Stambas J, Brown SA, Gutierrez A, Sealy R, Yue W, Jones B, Lockey TD, Zirkel A, Freiden P, Brown B, Surman S, Coleclough C, Slobod KS, Doherty PC, Hurwitz JL.

Vaccine. 2005 Mar 31;23(19):2454-64.

PMID:
15752831
27.

Subcutaneous administration of a recombinant vaccinia virus vaccine expressing multiple envelopes of HIV-1.

Slobod KS, Lockey TD, Howlett N, Srinivas RV, Rencher SD, Freiden PJ, Doherty PC, Hurwitz JL.

Eur J Clin Microbiol Infect Dis. 2004 Feb;23(2):106-10. Epub 2004 Jan 20.

PMID:
14735404
28.

Primary central nervous system lymphoma in a child with acute B-cell lymphoblastic leukaemia: consecutive Epstein-Barr virus-related malignancies.

Buckingham SC, Benaim E, Sandlund JT, Gan YJ, Freiden PJ, Behm FG, Ribeiro RC, Sixbey JW, Slobod KS.

Br J Haematol. 1998 May;101(2):345-8.

PMID:
9609533
29.

Expression of the human immunodeficiency virus type 1 primer binding sequence inhibits HIV-1 replication.

Kechli AM, Freiden PJ, Rossi JJ, Brenner MK, Choueiry MA, Garcia JV, Slobod KS.

Hum Gene Ther. 1998 Mar 1;9(4):587-90.

PMID:
9525319
30.

Mobilization of CD34+ progenitor cells by granulocyte colony-stimulating factor in human immunodeficiency virus type 1-infected adults.

Slobod KS, Bennett TA, Freiden PJ, Kechli AM, Howlett N, Flynn PM, Head DR, Srivastava DK, Boyett JM, Brenner MK, Garcia JV.

Blood. 1996 Nov 1;88(9):3329-35.

31.

In vivo expression of mammalian BiP ATPase mutants causes disruption of the endoplasmic reticulum.

Hendershot LM, Wei JY, Gaut JR, Lawson B, Freiden PJ, Murti KG.

Mol Biol Cell. 1995 Mar;6(3):283-96.

32.

Interconversion of three differentially modified and assembled forms of BiP.

Freiden PJ, Gaut JR, Hendershot LM.

EMBO J. 1992 Jan;11(1):63-70.

Supplemental Content

Loading ...
Support Center